Nagaya N
Nagaya Cardiovascular and Respiratory Clinic, Osaka, Japan.
Int Angiol. 2010 Apr;29(2 Suppl):14-8.
Prostacyclin has vasoprotective effects such as vasodilation and antiplatelet aggregatory activity. A relative deficiency of prostacyclin contributes to the pathogenesis of cardiovascular disease including pulmonary artery disease (PAH). Inconvenient intravenous dosing of prostacyclin led to the development of more stable, an orally active analogue: beraprost. It is a chemically stable prostacyclin analogue owing to its cyclo-pentabenzofuranyl structure and produces strong vasodilation and inhibition of platelet aggregation. To date, beraprost has been used in the treatment of PAH and peripheral arterial disease (PAD). Recently, we have shown that beraprost induces neovascularization in ischemic myocardium by enhancement of bone marrow cell mobilization. Interestingly, meta-analysis of clinical studies for PAD has shown that repeated administration of beraprost decreases the number of cardiovascular events. These results suggest that oral administration of beraprost has beneficial effects on cardiovascular disease. Orally active prostacyclin analogues, are promising drugs for the treatment of cardiovascular disease.
前列环素具有血管保护作用，如血管舒张和抗血小板聚集活性。前列环素相对缺乏会导致包括肺动脉疾病（PAH）在内的心血管疾病的发病机制。前列环素不方便的静脉给药方式促使人们开发出更稳定的口服活性类似物：贝拉前列腺素。由于其环戊苯并呋喃基结构，它是一种化学稳定的前列环素类似物，具有强大的血管舒张作用和抑制血小板聚集的作用。迄今为止，贝拉前列腺素已用于治疗PAH和外周动脉疾病（PAD）。最近，我们发现贝拉前列腺素通过增强骨髓细胞动员在缺血心肌中诱导新生血管形成。有趣的是，对PAD临床研究的荟萃分析表明，重复给药贝拉前列腺素可减少心血管事件的数量。这些结果表明，口服贝拉前列腺素对心血管疾病具有有益作用。口服活性前列环素类似物是治疗心血管疾病的有前景的药物。
